2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Value, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

3460 White blood cell count and NPM1/FLT3 mutational status modify associations between DNA methylation-based biological aging markers and survival in acute myeloid leukemia

Drew R Nannini, DO, PhD, Christopher C Oakes, PhD2, Ann-Kathrin Eisfeld, MD3, Tara L. Lin, MD4, Jesus D Gonzalez-Lugo, MD5
1 University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 University of Kansas Medical Center, Kansas City, Kansas, United States
5 University of Kansas Medical Center, Kansas City, Kansas, United States

Introduction: Acute myeloid leukemia (AML) is a biologically heterogeneous disease whose prognosis is largely determined by cytogenetic and molecular abnormalities. However, patients with similar genetic risk often experience different clinical outcomes, suggesting patient-related biological factors may provide prognostic information beyond established genetic and clinical risk factors. DNA methylation-based measures of biological age reflect age-related molecular changes and may complement these risk factors to improve prognostication. As these aging metrics capture distinct biological aspects of aging, we evaluated the association between six epigenetic markers of biological aging and overall survival (OS) in AML.

Methods: DNA methylation profiling was performed on mononuclear cells from bone marrow specimens using the Infinium MethylationEPIC BeadChip in 146 newly diagnosed AML patients (age 22-84) enrolled in the BEAT AML study who did not undergo leukapheresis or receive prior chemotherapy. Six principal component-based biological aging metrics were estimated from DNA methylation, representing intrinsic cellular aging (intrinsic epigenetic age acceleration [IEAA] and SkinBlood age acceleration [SkinBloodAA]), immune system aging (extrinsic epigenetic age acceleration [EEAA]), phenotypic and mortality associated aging (PhenoAge acceleration [PhenoAA] and GrimAge acceleration [GrimAA]), and telomere length attrition [TLA]. Multivariable Cox proportional hazards regression models were used to evaluate associations between OS and each aging metric, adjusting for age, sex, European LeukemiaNet (ELN) genetic risk classification, and white blood cell (WBC) count at diagnosis. Interaction and stratified analyses assessed effect modification by ELN risk, WBC count, and NPM1/FLT3-ITD mutational status.

Results: Multiple biological aging metrics demonstrated significant interactions with WBC count, including IEAA (P=0.040), SkinBloodAA (P=0.017), EEAA (P=0.022), PhenoAA (P=0.040), and TLA (P=0.022). Among patients with high WBC count or hyperleukocytosis (WBC > 40×10?/L), greater PhenoAA (hazard ratio [HR] 1.01, P=0.043) was associated with poorer OS, whereas greater TLA (HR 0.53, P=0.043) was associated with improved OS. In contrast, among patients with mild-to-moderate leukocytosis (WBC 11-40×10?/L), greater SkinBloodAA (HR 0.97, P=0.006) was associated with improved OS while greater TLA (HR 3.07, P=0.041) was associated with poorer OS. Among patients without leukocytosis (WBC < 11×10?/L), greater TLA (HR 0.32, P=0.050) exhibited improved OS. Greater IEAA (HR 1.01, P=0.063) and EEAA (HR 1.01, P=0.079) also showed a trend toward poorer OS among patients with high WBC count or hyperleukocytosis.

NPM1/FLT3-ITD mutational status significantly modified the associations between IEAA (P=0.042), EEAA (P=0.041), PhenoAA (P=0.008), GrimAA (P<0.001), and TLA (P=0.025) on OS. Among patients with NPM1+/FLT3-ITD+, greater IEAA (HR 0.98, P=0.047), EEAA (HR 0.98, P=0.036), PhenoAA (HR 0.97, P=0.039), and GrimAA (HR 0.88, P=0.002) were associated with improved OS while greater TLA (HR 4.77, P=0.019) was associated with poorer OS. Conversely, in patients with NPM1-/FLT3-ITD- and NPM1-/FLT3-ITD+, greater PhenoAA (HR 1.01, P=0.030; HR 1.05, P=0.008) and GrimAA (HR 1.04, P=0.016; HR 1.21, P=0.002) were significantly associated with poorer OS, respectively. No aging metric was associated with OS among patients with NPM1+/FLT3-ITD-. No significant associations were observed in the primary analyses (non-interaction) or by ELN risk.

Conclusion: In this analysis, WBC count and NPM1/FLT3 mutational status modified the associations between DNA methylation-based biological aging and OS in AML. The association between biological aging and survival was not uniform but varied according to leukocyte burden, possibly reflecting differences in systemic inflammatory signaling, immune activation, and leukemia–host interactions across levels of disease burden. The divergent associations by NPM1/FLT3 mutational subgroups suggest that the prognostic utility of biological aging depends on the molecular profile of AML, supporting the integration of epigenetic aging with leukemia genetics to further refine risk stratification. As these metrics capture distinct aspects of aging, our findings support continued evaluation of DNA methylation-based aging biomarkers to improve AML prognostication beyond established genetic and clinical risk factors.

Drew R Nannini, DO, PhD: No relevant conflicts of interest to declare.